Avalyn raises $175m in funding to develop inhaled IPF drugs

27 Sep 2023
www.pharmaceutical-technology.com
Phase 1Phase 2Phase 3Orphan DrugClinical Result
Avalyn raises $175m in funding to develop inhaled IPF drugs
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Avalyn raises $175m in funding to develop inhaled IPF drugs
Preview
Source: Pharmaceutical Technology
With a limited number of approved drugs for IPF in the market, Esbriet and Ofev dominate the sales in the field. Image Credit: eamesBot / Shutterstock.
Avalyn Pharma secured $175m in a Series C financing round to fund the clinical development of inhaled pulmonary therapies.
The US-based company plans to advance idiopathic pulmonary fibrosis (IPF) therapies, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), to Phase IIb and IIa trials, respectively.
Approved oral drugs—Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib)—are commonly used to reduce scarring. Avalyn is developing inhaled formulations in an effort to reduce the systemic side effects of the drugs. Avalyn CEO Lyn Baranowski highlighted the need for an alternate mode of administration stating: “Fewer than 30% of patients in the US are treated with either of the two approved oral medicines today due to their significant tolerability challenges.”
AP01 is currently in an open-label extension of the Phase Ib trial in IPF patients, whilst AP02 has been evaluated in a Phase I study with healthy volunteers.
With a limited number of approved drugs for IPF in the market, Esbriet and Ofev dominate the sales in the field. Esbriet generated SFr119m ($129.5m) in sales in H1 2023, as per Roche’s financials.
However, there are more than 300 drugs currently in development to treat IPF, with 30% of these drugs currently in clinical development (Phase I or later), as per GlobalData.
GlobalData is the parent company of Pharmaceutical Technology.
Other drugs currently in development for IPF include Redx Pharma’s zelasudil (RXC007), which was granted orphan drug designation by the US Food and Drug Administration (FDA) based on Phase II data. United Therapeutic’s Tyvaso (treprostinil) is also being studied in two Phase III trials (NCT04708782 and NCT04905693).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.